NCT06927960Phase 1Completed
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- AnHorn Medicines Co. Ltd.
- Participants (registry)
- 64
- Start
- March 2025
- Primary completion
- July 2025
- Study completion
- July 2025
- Last registry update
- December 2025
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: AH-001 or placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.